Physician profile
Rayane Nassar
NPI 1841429370
$1,507.74
in general payments reported to CMS, 2019-2025
22 companies · $59.09 in 2025
The $59.09 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $327 · 2021: $304 · 2022: $148 · 2023: $59.69 · 2024: $102 · 2025: $59.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200 · Education: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.40 |
| Education | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $209.72 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $184.11 | 2019-2022 | |
| Akebia Therapeutics INC | $183.46 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.57 | 2021-2024 | |
| Amgen INC. | $126.52 | 2019-2022 | |
| Vifor Pharma, INC. | $103.20 | 2019-2021 | |
| Glaxosmithkline, LLC. | $72.34 | 2024-2025 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $68.23 | 2019-2020 | |
| Daiichi Sankyo INC. | $68.13 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $48.56 | 2019 | |
| Mallinckrodt Hospital Products INC. | $45.36 | 2021-2022 | |
| Travere Therapeutics, INC. | $42.56 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.94 | 2023 | Gattex |
| Otsuka America Pharmaceutical, INC. | $34.09 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $24.75 | 2023 | Tarpeyo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $19.31 | 2019 | |
| Nxstage Medical, INC. | $16.91 | 2024 | |
| Novo Nordisk INC | $16.16 | 2024 | Rivfloza |
| Amicus Therapeutics, INC. | $14.93 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.81 | 2019 | |
| Genentech USA, INC. | $13.37 | 2019 | |
| Abbott Laboratories | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rayane Nassar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.